On the way to in vitro platelet production.
Transfus Clin Biol
; 25(3): 220-227, 2018 Sep.
Article
em En
| MEDLINE
| ID: mdl-30150135
ABSTRACT
The severely decreased platelet counts (10-30.103 platelets/µL) frequently observed in patients undergoing chemotherapy, radiation treatment or organ transplantation are associated with life-threatening increased bleeding risks. To circumvent these risks, platelet transfusion remains the treatment of choice, despite some limitations which include a limited shelf-life, storage-related deterioration, the development of alloantibodies in recipients and the transmission of infectious diseases. A sustained demand has evolved in recent years for controlled blood products, free of infectious, inflammatory and immune risks. As a consequence, the challenge for blood centers in the near future will be to ensure an adequate supply of blood platelets, which calls for a reassessment of our transfusion models. To meet this challenge, many laboratories are now turning their research efforts towards the in vitro and customized production of blood platelets.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Plaquetas
/
Técnicas de Cultura de Células
Limite:
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article